

Featured Research & News


Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024

Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024

Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024

Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024


Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024

Neural Mechanisms of Neuroplasticity
New imaging reveals how psilocybin promotes neural connectivity in mood
Oct 8, 2024

MDMA for PTSD: Seeking Participants
Enrolling veterans and first responders for groundbreaking PTSD therapy study
Oct 1, 2024

Nature Medicine
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Sept 28, 2024

Training
Psychedelic medecine Fellowship
Comprehensive training program for the next generation of psychedelic researchers and clinicians
COMMUNITY
Neural Mechanisms of Neuroplasticity
Phase 2b trial shows 71% of participants experiencing significant symptom reduction
COLLABORATION
YPPS Ecosystem & Partnerships
Building interdisciplinary networks to advance psychedelic science and medicine
At ENACT, research is a dynamic, lived experience that connects people, ideas, and discoveries. Our homepage serves as an entryway into this interconnected world, where knowledge is not just generated but enacted into meaningful change.
Our tagline, “Enacting Impact Through Research,” crystallizes this fundamental relationship between discovery and action. It speaks to our methodology—how we create spaces that foster deep collaboration, cultivate intersections of thought and practice, and sustain the continuous flow between inquiry and application.

